Tekmal, Rajeshwar RaoSchool of Medicine |
![]() |
After receiving his Ph.D. in biochemistry from the N.D.R.I./Kurukshetra University, India in 1982, Dr. Tekmal completed postdoctoral training in molecular biology at Michigan State University and the University of Mississippi Medical Center. He started his independent academic research career at Oakland University in Michigan and in 1989, joined the ob-gyn faculty at the UT Health Science Center at San Antonio for the first time. After six years, Dr. Tekmal moved to Emory University in Atlanta, where he achieved the rank of professor (tenured) and led the Breast Cancer Research Program at Emory?s Winship Cancer Research Institute. In 2003, the UT Health Science?s Ob-Gyn department recruited Dr. Tekmal to return to San Antonio to start a Division of Reproductive Research.
|
1/2005 - Present | Carl J. Pauerstein Professorship in Reproductive Research and Research Professor | The University of Texas Health Science Center at San Antonio, Ob-Gyn, San Antonio, TX |
1/2005 - Present | Research Professor | University Health System, San Antonio, TX |
7/2004 - Present | Faculty Member | University of Texas Health Science Center San Antonio, San Antonio, TX |
6/2003 - Present | Professor (Tenured) and Other | The University of Texas Health Science Center at San Antonio, Ob-Gyn, San Antonio, TX |
6/2003 - Present | Member | Cancer Therapy and Research Center, San Antonio, TX |
6/2003 - Present | Director and Director, Division of Reproductive Research | The University of Texas Health Science Center at San Antonio, Division of Reproductive Research, Ob-Gyn, San Antonio, TX |
Year | Degree | Discipline | Institution |
1987 | Postdoctoral Fellowship | Molecular Biology (Mentor: Dr. L. I. Slobin) | Department of Biochemistry, University of Mississippi Medical Center Jackson , MS |
1984 | Postdoctoral Fellowship | Molecular Genetics (Mentor Dr. C. A. Reddy) | Department of Microbiology and Public Health, Michigan State University East Lansing , MI |
1982 | PhD | Biochemistry | National Dairy Research Institute- Kurukshetra University India |
1977 | MS | Biological Sciences (Passed M.Sc with Distinction) | Osmania University Hyderabad , India |
1975 | BS | Biological Sciences | Osmania University Hyderabad , India |
Hormone- Mediated Action and Hormonal Cacinogenesi- My major research focus and expertise is in the area of hormone-mediated action and hormonal carcinogenesis with special emphasis on the etiological role of tissue estrogen in breast and gynecological malignancies. |
In vivo transgenic Model and Preclinical Models- Using out in vivo transgenic model and preclinical models, ongoing studies focus on the importance of local estrogen and estrogen receptors in estrogen-mediated transformation, the synergistic role of estrogen with tumor suppressor and cell cycle genes in accelerating the disease, and examining whether inducing estrogen/ estrogen receptor beta results in the prevention/ reduction in the risk of developing breast cancer or overcoming resistance to endocrine therapies. |
Professorship- My teaching activities included instruction to both undergraduate and graduate students and in addition didactic teaching to medical residents and fellows. |
Role of CSF-1 and its receptors- Our studies focus on the role of CSF-1 and its receptor, c-fms, in breast, cervical and ovarian cancer as well as in endometriosis. Etiological role of CSF-1 and its receptor as well as CD44-Hylaronic acid in the early endometriotic lesion formation is being investigated. |
Date | Description | Institution | # Students |
8/2016 - Present | Post-Doctoral Student Supervision | Emory University | |
8/2016 - Present | Post-Doctoral Student Supervision | University of Texas Health Science Center- San Antonio | |
8/2016 - Present | Post-Doctoral Student Supervision | University of Texas Health Science Center- San Antonio | |
8/2011 - Present | CSBL 601 Gynecological Cancers | 15 students | |
Co-Course Director - Selective Topics in oncology. (Full Semester) | |||
8/2011 - Present | Journal Club (Cancer Track) | 25 students | |
Co-Course Director - Fall and spring semesters. | |||
8/2003 - Present | Didactic lectures on: Molecular/Biochemical Methods in Reproductive Research | 2 students | |
Course Director - Offered to Ob-Gyn Reproductive Endocrinology fellows every year. |
Abstract |
Samayoa C, Krishnegowda NK, Vadlamudi RK, Tekmal RR. Investigating the role of estrogen receptor β agonists in the prevention and treatment of breast cancer; 2016 Jan. (Proc.Am.Assn.Cancer Research 107th Annual Meeting). |
Vadlamudi RK, Sareddy GR, Viswanadhapalli S, Lee T-K, Ma S-H, Lee WR, Mann M, Krishnan SR, Gonugunta V, Liu Y, Strand DW, Tekmal RR, Ahn J-M, Raj GV. ESR1 coregulator binding inhibitor (ECBI) a novel agent for treating hormone therapy resistant breast cancer; 2016 Jan. (Proc.Am.Assn. Cancer Research 107th Annual Meeting). |
Knudtson J, Tellez M, Binkley PA, Tekmal RR, Schenken RS. Hyaluronic acid synthesis and degradation in endometrial epithelial and stomal cells from women with and without endometriosis; 2016 Jan. (Reproductive Science; vol. 23). |
Knudtson J, Tellez M, Binkley PA, Tekmal RR, Schenken RS. Impaired development of endometriotic lesions in CD44 knockout mice; 2015 Jan. (Reproductive Science). |
Samayoa C, Krishnegowda NK, Vadlamudi RK, Tekmal RR. Investigating the therapeutic use of estrogen receptor β agonists in breast cancer; 2015 Jan. (38th Annual SABC Symposium). |
Vadlamudi RK, Sareddy GR, Viswanadhapalli S, Lee T-K, Ma S-H, Lee WR, Mann M, Krishnan SR, Gonugunta V, Strand DW, Tekmal RR, Ahn J-M, Raj GV. ESR1 coregulator binding inhibitor (ECBI) as a novel therapeutic to target hormone therapy resistant metastatic breast cancer; 2015 Jan. (38th Annual SABC Symposium). |
Samayoa C, Krishnegowda N, Vadlamudi RK, Tekmal RR. Evaluating estrogen receptor β agonists for the treatment of breast cancer; 2015 Jan. (Proc.Am.Assn. Cancer Research 106th Annual Meeting). |
Sareddy GR, Gruslova A, Cavazos DA, Tekmal RR, Brenner AJ, Vadlamudi RK. LY500307 as a novel therapeutic agent for treatment of glioblastoma; 2015 Jan. (Proc.Am.Assn. Cancer Research 106th Annual Meeting). |
Sareddy GR, Chavez JE, Salazar H, Mann M, Hernandez J, Ramakrishnan SR, Kost E, Tekmal RR, Vadlamudi RK. Therapeutic efficacy of ERβ agonists on ovarian cancer; 2014 Jan. (Proc.Am.Assn. Cancer Research 105th Annual Meeting; vol. 606). |
Bowers LW, Brenner AJ, Hursting SD, Tekmal RR, deGraffenried LA. Obesity-associated systemic interleukin-6 promotes pre-adipocyte aromatase expression via increased breast cancer cell prostaglandin E2 production; 2014 Jan. (37th Annual SABC Symposium). |
Samayoa C, Krishnegowda NK, Vadlamudi RK, Tekmal RR. Estrogen receptor β agonists reduce breast cancer tumor growth in syngeneic mouse models; 2014 Jan. (37th Annual SABC Symposium). |
Knudtson J, Tellez M, Binkley PA, Tekmal RR, Schenken RS. Endometrial epithelial cell expression of estrogen receiptor isoforms alpha and beta alters attachment to peritoneal mesothelial cells; 2014 Jan. (Fertility & Sterility). |
Hsu Y-T, Liu J, Binkley PA, Schenken RS, Tekmal RR, Huang TH-M, Kirma NB. Parallel EMT pathways mediated by epidermal growth factor, EpCAM and mesenchymal cadherins in benign endometriotic lesions and endometrial cancer; 2014 Jan. (Proc.Am.Assn. Cancer Research 105th Annual Meeting). |
Samayoa C, Krisnegowda N, Ramakrishnan SR, Vadlamudi RK, Tekmal RR. S-equol, an estrogen receptor β agonist, inhibits tumor growth and progression of breast cancer; 2014 Jan. (Proc.Am.Assn. Cancer Research 105th Annual Meeting). |
Journal Article |
Knudtson JF, Tekmal RR, Santos MT, Binkley PA, Krishnegowda N, Valente P, Schenken, RS. Lack of CD44 expression results in impaired development of early endometriotic lesions in CD44 knockout mice Repro Science 2016 Jan;:87-91. |
Kost ER, Valente PT, Lynch BA, Krisnegowda N, Hertz AM, Hall KL, Riddle ND, Tekmal RR. The etiology of endometrial cancer in young Hispanic women Int J Gynecol Cancer 2016 Jan;:1129-1136. |
Bowers LW, Megan W, Brenner AJ, Tekmal RR, Rossi EL, Hursing SD, deGraffenried LA. Obesity suppresses estrogen receptor beta in breast cancer cells via HER2 PLoSOne 2015 2015 Dec;. |
Bowers LW, Brenner AJ, Hursting SD, Price RS, Tekmal RR, deGraffenried LA. Interleukin-6 promotes pre-adipocyte aromatase expression via increased breast cancer cell prostaglandin E2 Breast Cancer Research and Treatment 2015 Jan;:49-57. |
Gonugunta VK, Sareddy GR, Ramakrishnan SR, Cortez V, Roy SS, Tekmal RR, Vadlamudi RK. Inhibition of mTOR signaling reduces PELP1 mediated tumor growth and therapy resistance Molecular Cancer Therapeutics 2014 Jan;:1578-1588. |
Cortez V, Samaoa C, Zamora A, Martinez L, Tekmal RR, Vadlamudi RK. PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma Cancer Research 2014 Jan;74:7395-7405. |
Roy SS, Kirma NB, Santhamma B, Tekmal RR, Agyin JK. BU-32: a novel proteosome inhibitor for treatment of multiple myeloma Cancer Chemotherapy Pharmacology 2014 Jan;. |
Nair BC, Ramakrishnan SR, Sareddy GR, Mann M, Xu B, Natarajan M, Hasty P, Brann D, Tekmal RR, Vadlamudi RK. Proline, Glutamic acid, Leucine rich Protein-1 (PELP1) is essential for optimal p53-mediated DNA Damage Response Cell Growth and Differentiation (Nature Publishing Group) 2014 Jan;:1409-1418. |
Bowers LW, Maximo IXF, Brenner AJ, Jolly CA, Beeram M, Hursting SD, Price RS, Tekmal RR, deGraffenried LA. NSAID use attenuates breast cancer recurrence in overweight and obese women: Role of prostaglandin-aromatase interactions Cancer Research 2014 Jan;:4446-4457. |
Yuan B, Cheng L, Chiang H-C, Xu X, Han Y, Su H, Wang L, Zhang B, Lin J, Li X, Wang T, Tekmal RR, Curiel TJ, Hu Y, Ye Q, Li R. Mobilizing the antitumor activity of estrogen receptor β through a phosphotyrosine switch J Clinical Invest 2014 Jan;:3378-3390. |
Mansouri HA, Kirma NB, Binkley PA, Krishnegowda NK, Tekmal RR. Macrophase Colony-Stimulating Factor Modulates Matrix metalloproteinase 2 and 9 Expression in Endometrial Epithelial Cells Gynecol Obstet (Sunnyvale) 2014 Jan;. |
Vallabeaneni, S., Nair, B.C., Cortez, V., Challa, R., Chakravarty, D., Tekmal R.R., and Vadlamudi, R.K. Significance of ER-Src axis in hormonal therapy resistance Brast Cancer Research Treatment 2011 Nov;130(2):377-385. |
Nair BC, Nair SS, Chakravarty D, Challa R, Manavathi B, Yew PR, Kumar R, Tekmal RR, Vadlamudi RK. Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1 Cancer Res 2010 Sep;70(18):7166-7175. |
Federal |
|
Funding Agency | NIH/NCI |
Title | Cancer Therapy and Research Center at UTHSCSA - Cancer Center Support Grant Program Leader (Women`s Cancer) |
Status | Active |
Period | 8/2006 - Present |
Role | Principal Investigator |
Grant Detail | |
Funding Agency | CPRIT |
Title | Development and testing novel inhibitor for ER activator PELP-1 |
Status | Active |
Period | 2/2015 - Present |
Role | Co-Investigator |
Grant Detail | |
Funding Agency | NIH/NCI |
Title | Novel ERβ agonists for the treatment of gliomas |
Status | Active |
Period | 9/2014 - 8/2019 |
Role | Co-Investigator |
Grant Detail | RO1 CA178499 |
Private |
|
Funding Agency | Bill & Melinda Gates Foundation/Evestra, Inc. |
Title | Testing the efficacy of novel steroid compounds as a long-acting birth control agents |
Status | Active |
Period | 12/2015 - 11/2017 |
Role | Principal Investigator |
Grant Detail | |